According to the sources, Bharat Biotech which has completed the Phase 2/3 trials of Covid-19 vaccine Covaxin for use in children under 18 years of age has submitted the data to the Central Drugs Standard Control Organisation for its verification and subsequent approval for Emergency Use Authorisation
In a study of 614 fully vaccinated health workers in India discovered a "significant" drop in their COVID-fighting antibodies within four months of the first shot.
This findings might help the Indian government to decide whether to provide booster doses. Some of the Western countries have done.
Covid-19 in India may be entering some kind of stage of endemicity where there is low or moderate level of transmission going on, Chief Scientist of the World Health Organisation Dr Soumya Swaminathan said.
The endemic stage is when a population learns to live with a
Union health minister Mansukh Mandaviya on Thursday said the government has launched an inquiry into a report claiming that counterfeit versions of Covishield, India’s primary anti-COVID-19 vaccine, had been seized.
“It has been claimed that duplicate versions of Covishield vaccine were sold in the country. The
India has done better than any country in the world as regards to affordability and the reach to the people of COVID-19 vaccines, Bharat Biotech Chairman and Managing Director Krishna Ella said on Sunday.
Highlighting the enormity of the task of vaccination, Ella said, “When you
Covaxin, Bharat Biotech’s Covid 19 vaccine works with the new Delta variant of the virus, finds a new study published by the Indian Council of Medical Research. In medical lingo, the Delta variant is referred to as B.1.617.2. Not only is it highly contagious, but
The Indian government has placed the largest order of vaccines so far. According to reports, it is procuring 660 million doses of Covaxin and Covishield the estimated worth of which is 145.05 billion Indian Rupees. This would help it meet the projections it has made
India’s Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, the US’ National Institute of Health has said. The NIH said results of two studies of blood serum from people who
The decision regarding enhancing interval between two doses of Covishield was based on scientific evidence and taken in a transparent manner, NTAGI Chair N K Arora said on Tuesday.
There was no dissenting voice among the members of the National Technical Advisory Group on Immunization (NTAGI
The recruitment for the clinical trial of the country’s first indigenously-developed COVID-19 vaccine, Covaxin, among children in the age group of 6-12 years will begin at the AIIMS here from Tuesday.
This will be followed by the clinical trial of children in the age-group of 2-6